IACM-Bulletin du 10 Août 2019 Science/Homme: La consommation de cannabis à l'adolescence n'est pas associée à des changements structurels du cerveau à l'âge adulte Science/Homme: La consommation de cannabis réduit le risque de cancer chez les patients atteints de la maladie de Crohn Etats-Unis: Les États veulent que le cannabis devienne plus vert alors que le cannabis légal se développe Science/Homme: La consommation de cannabis est associée à une réduction du taux d'insuline à jeun chez les personnes souffrant d’obésité. En bref Un coup d'œil sur le passé Science/Homme: La consommation de [...]
Lire la suiteThe Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series Joseph El-Khoury & Nayiri Sahakian Journal of Psychoactive Drugs, 2015, 47, 4, 286-292 https://doi.org/10.1080/02791072.2015.1073815 Abstract The association of substance abuse and psychotic disorders is of interest to clinicians, academics, and lawmakers. Commonly abused substances, such as cannabis, cocaine, amphetamines, and alcohol, have all been associated with substance-induced psychosis. Hallucinogens can induce desired psychedelic effects and undesirable psychomimetic reactions. These are usually transient and resolve once the duration of action is over. Sometimes, these effects persist, causing distress and requiring intervention. This article focuses on the hallucinogenic substance Salvia divinorum, [...]
Lire la suiteChronic, Intermittent Microdoses of the Psychedelic N,N‑Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents Lindsay P. Cameron, Charlie J. Benson, Brian C. DeFelice, Oliver Fiehn, and David E. Olson ACS Chemical Neurosciences, 2019 DOI: 10.1021/acschemneuro.8b00692 ABSTRACT : Drugs capable of ameliorating symptoms of depression and anxiety while also improving cognitive function and sociability are highly desirable. Anecdotal reports have suggested that serotonergic psychedelics administered in low doses on a chronic, intermittent schedule, so-called “microdosing”, might produce beneficial effects on mood, anxiety, cognition, and social interaction. Here, we test this hypothesis by subjecting male and female Sprague Dawley rats to behavioral testing following the [...]
Lire la suitePowerful substances in tiny amounts: Exploring the practice of microdosing psychedelic drugs Petter Grahl Johnstad Working Paper · December 2017 Nordic Studies on Alcohol and Drugs, 2018, Vol. 35(1) 39–51. Doi : 10.1177/1455072517753339 This article presents an explorative study of microdosing practices with psychedelic drugs. A microdose is defined as a sub-perceptual dose, commonly about one tenth of an ordinary recreational dose, which gives no alteration of consciousness or feeling of intoxication. Respondents (n = 17) were recruited at several Internet fora for individual interviews mediated via private messaging. Every participant was male, and the median respondent was in his 30s with a stable job [...]
Lire la suiteMotives and Side-Effects of Microdosing With Psychedelics Among Users Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder, Kim P. C. Kuypers International Journal of Neuropsychopharmacology, 2019, 1–9 doi:10.1093/ijnp/pyz029 Abstract Background : Microdosing with psychedelics has gained considerable media attention where it is portrayed as a performance enhancer, especially popular on the work floor. While reports are in general positive, scientific evidence about potential negative effects is lacking aside from the prevalence and motives for use. The present study addressed this gap by surveying psychedelic users about their experience with microdosing including their dosing schedule, motivation, and potential experienced negative effects. Methods : An [...]
Lire la suiteThe abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks, Jack E. Henningfiel Neuropharmacology, 2018, 142, 143-166. https://doi.org/10.1016/j.neuropharm.2018.05.012 a b s t r a c t This review assesses the abuse potential of medically-administered psilocybin, following the structure of the 8 factors of the US Controlled Substances Act (CSA). Research suggests the potential safety and efficacy of psilocybin in treating cancer-related psychiatric distress and substance use disorders, setting the occasion for this review. A more extensive assessment of abuse potential according to an 8-factor analysis would eventually be required to [...]
Lire la suitePsychedelic Induced Transpersonal Experiences, Therapies, and Their Implications for Transpersonal Psychology Thomas B. Roberts and Michael J. Winkelman Chapter 25 - The Wiley-Blackwell Handbook of Transpersonal Psychology, First Edition. Edited by Harris L. Friedman and Glenn Hartelius. © 2013 John Wiley & Sons, Ltd. Published 2013 by John Wiley & Sons, Ltd. Psychedelics and other natural and synthetic substances have an ability to induce a range of transpersonal experiences. The predominance of spiritually-related experiences from these substances has led to the development of the concept of entheogen— reflecting their potential to produce an internal experience of communing with god. The similarity of the drug-induced transpersonal [...]
Lire la suiteHomological scaffolds of brain functional networks G. Petri, Paul Expert, F. Turkheimer, Robin Carhart-Harris, David Nutt, P.J. hellyer, F. Vaccarino Journal of The Royal Society, Interface, 2014, 11, 20140873 Published : 06 December 2014 https://doi.org/10.1098/rsif.2014.0873 Abstract Networks, as efficient representations of complex systems, have appealed to scientists for a long time and now permeate many areas of science, including neuroimaging (Bullmore and Sporns 2009 Nat. Rev. Neurosci.10, 186–198. (doi:10.1038/nrn2618)). Traditionally, the structure of complex networks has been studied through their statistical properties and metrics concerned with node and link properties, e.g. degree-distribution, node centrality and modularity. Here, we study the characteristics of functional brain networks at [...]
Lire la suiteThe Consciousness Research of Stanislav Grof : A Cosmic Portal Beyond Individuality Richard Yensen & Donna Dryer 1998 I. Introduction Stanislav Grof began his research in Prague, Czechoslovakia, as a psychiatric resident, in the late 1950’s. His initial observations seemed to confirm and offer a laboratory proof for many of the basic tenets of Freudian psychoanalytic thought. At that time his conclusion was politically unsettling because psychoanalysis was repressed in the iron curtain countries. Forty years later the outcome of Grof’s continued research is a theoretical framework for understanding human consciousness. His theory has evolved into a wide-ranging description of the relationship between the individual [...]
Lire la suiteThe Pharmacology of Lysergic Acid Diethylamide : a Review Torsten PASSIE, John H. HALPERN, Dirk O. STICHTENOTH, Hinderk M. EMRICH, Annelie HINTZEN CNS Neuroscience & Therapeutics, 2008, 14, 295-314. Doi: 10.1111/j.1755-5949.2008.00059.x Lysergic acid diethylamide (LSD) was synthesized in 1938 and its psychoactive effects discovered in 1943. It was used during the 1950s and 1960s as an experimental drug in psychiatric research for producing so-called “experimental psychosis” by altering neurotransmitter system and in psychotherapeutic procedures (“psycholytic” and “psychedelic” therapy). From the mid 1960s, it became an illegal drug of abuse with widespread use that continues today. With the entry of new methods of research and [...]
Lire la suite